---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062077"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:31:08.914741+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q3 revenue down 21% to $37.9M; launches strategic review with Goldman Sachs

## Summary
- Q3 2023 revenue $37.9M, down 21% YoY; net loss $50.3M vs $45.3M; Adjusted EBITDA loss $29.8M vs $25.9M.
- MRD revenue $24.7M (+24% YoY); Immune Medicine revenue $13.3M (-52% YoY); clonoSEQ test volume +56% to 15,072.
- Strategic review of MRD and Immune Medicine businesses underway with Goldman Sachs to maximize shareholder value.
- Full-year 2023 guidance: MRD revenue $100-105M; total operating expenses ~$375M; Immune Medicine revenue guidance removed.
- Discovered novel multiple sclerosis target, validating autoimmune target discovery approach.

## SEC filing metadata
- accession: 0000950170-23-062077
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017023062077/0000950170-23-062077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017023062077/adpt-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062077
- JSON: https://secwatch.observer/filing/0000950170-23-062077.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062077.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp reported the quarter ended September 30, 2023 results: revenue $37.9 million, net income $50.3 million. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2023
  - Revenue: $37.9 million
  - Net income: $50.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue was $37.9 million for the quarter ended September 30, 2023, representing a 21% decrease from the third quarter in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017023062077/0000950170-23-062077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.